We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Rapid Blood Test Indicates Cellular Immunity to SARS-CoV-2 Within 48 Hours

By LabMedica International staff writers
Posted on 21 Jul 2022

A new blood test can indicate a person's status of cellular immunity to SARS-CoV-2 within just 48 hours and also whether the immunity is the result of vaccination against SARS-CoV-2 or of survived infection. More...

The test is particularly relevant for vulnerable patient groups, whose own antibody response is not meaningful.

The new test, developed by a research team at Medical University Vienna (Austria), is based on the memory response of T cells to three different SARS-CoV-2 peptide mixtures. T cells are an important part of the specific cellular immune defense: they eliminate cells infected with SARS-CoV-2 and support antibody production by B cells. The new test will particularly useful for those who are unable to produce antibodies against SARS-CoV-2. Analyses of blood samples from COVID-19-recovered patients, based on peptide mixtures of S-, M- and NC-proteins, enabled the research team to not only detect the two antiviral cytokines interleukin (IL)-2 and interferon-gamma in large quantities but also to identify the cytokine IL-13 as a marker for the highly specific T-cell immune response against SARS-CoV-2. IL-13 was previously known as a marker for allergic immune responses, but it apparently also plays a key role in establishing a long-lasting antibody response.

By using the three different peptide mixtures, it is also possible to discriminate between those who have been vaccinated against SARS-CoV-2 and those who have had COVID-19. Samples from recovered volunteers responded with significant cytokine production to all three peptide mixtures, whereas samples from vaccinated volunteers only responded to the specific peptide mixture in which the protein was induced by vaccination (S protein), and to which the vaccinated subjects then went on to build up cellular immunity. The novel test, therefore, allows a specific cellular immune response to SARS-CoV-2 to be identified even in individuals who, for various reasons, are unable to develop meaningful antibody responses.

In a study, the T-cell response was also analyzed 10 months after infection. It was found that the T-cell response was still as strong as that measured 10 weeks after an infection. This is remarkable in that antibody levels in the blood have already dropped significantly 10 months after infection. This long-lasting T-cell response may protect against severe disease in the event of re-infection with SARS-CoV-2. The results of the study make a significant contribution to understanding the immune response to SARS-CoV-2 and will help quickly establish whether specific individuals have built up cellular immunity to SARS-CoV-2.

"Currently, it takes at least a week to perform and evaluate such T-cell tests, and the tests can only be performed in specialized laboratories. In contrast, our newly developed test is performed directly with a whole blood sample and can be evaluated after only 48 hours," said study leader Winfried Pickl.

Related Links:
Medical University Vienna 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.